Aerosolized cidofovir is retained in the respiratory tract and protects mice against intranasal cowpox virus challenge

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 9, 2003, Pages 2933-2937

  Roy, Chad J ^a   Baker, Robert ^a   Washburn, Kenneth ^b   Bray, Mike ^c  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b Stillmeadow Corp   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 14; CIDOFOVIR;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; COWPOX VIRUS; DOSE TIME EFFECT RELATION; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RETENTION; DRUG TISSUE LEVEL; FEMALE; INTERMETHOD COMPARISON; ISOTOPE LABELING; KIDNEY; MOUSE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; RESPIRATORY TRACT INFECTION; SMALLPOX; TISSUE DISTRIBUTION; VIRUS INFECTION; VIRUS REPLICATION;

ADMINISTRATION, INTRANASAL; AEROSOLS; ANIMALS; ANTIVIRAL AGENTS; COWPOX; COWPOX VIRUS; CYTOSINE; FEMALE; INJECTIONS, SUBCUTANEOUS; KIDNEY; LUNG; MICE; MICE, INBRED BALB C; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; RESPIRATORY SYSTEM; TISSUE DISTRIBUTION;

EID: 0041922641     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.9.2933-2937.2003     Document Type: Article

References (25)

1. Baker, R., M. Bray, and J. Huggins. 2003. Potential antiviral therapeutics for smallpox and other orthopoxvirus infections. Antiviral Res. 57:13-23.
2. Bray, M., M. Martinez, D. Kefauver, M. West, and C. Roy. 2002. Treatment of aerosolized cowpox virus infection in mice with aerosolized cidofovir. Antivir. Res. 54:129-142.
3. Bray, M., M. Martinez, D. Smee, D. Kefauver, E. Thompson, and J. Huggins. 2000. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. J. Infect. Dis. 181:10-19.
4. Cundy, K. C., Z. H. Li, M. J. Hitchcock, and W. A. Lee. 1996. Pharmacokinetics of cidofovir in monkeys: evidence for a prolonged elimination phase representing phosphorylated drug. Drug Metab. Dispos. 24:738-744.
5. Cundy, K. C., G. Lynch, and W. A. Lee. 1997. Bioavailability and metabolism of cidofovir following topical administration to rabbits. Antivir. Res. 35:113-122.
6. Cundy, K. C. 1999. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin. Pharmacokinet. 36:127-143.
7. Cundy, K. C., A. Bidgoo, G. Lynch, J. Shaw, L. Griffin, and W. A. Lee. 1996. Pharmacokinetics, bioavailability, metabolism and tissue distribution of cidofovir (HPMPC) and cyclic HPMPC in rats. Drug Metab. Dispos. 24:745-752.
8. De Clercq, E. 2002. Cidofovir in the treatment of poxvirus infections. Antivir. Res. 55:1-13.
9. De Clercq, E. 2002. Cidofovir in the therapy and short-term prophylaxis of poxvirus infections. Trends Pharmacol. Sci. 23:456-458.
10. Fenner, F., D. A. Henderson, I. Arita, Z. Jezek, and I. D. Ladnyi. 1988. Smallpox and its eradication. World Health Organization, Geneva, Switzerland.
11. Hayden, F., L. Gubareva, A. Monto, et al. 2000. Inhaled zanamavir for the prevention of influenza in families. N. Engl. J. Med. 343:1282-1289.
12. Henderson, D. A. 1998. Bioterrorism as a public health threat, 1998. Emerg. Infect. Dis. 4:488-492.
13. Henderson, D. A. 1999. Smallpox as a biological weapon: medical and public health management. JAMA 281:2127-2137.
14. Ho, H. T., K. Woods, J. Bronson, H. De Boeck, J. Martin, and M. Hitchcock. 1992. Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. Mol. Pharmacol. 41:197-202.
15. Jackson, R. J., A. Ramsay, C. Christensen, S. Beaton, D. Hall, and I. Ramshaw. 2001. Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox. J. Virol. 75:1205-1210.
16. Lacy, S. A., M. J. Hitchcock, W. A. Lee, P. Tellier, and K. C. Cundy. 1998. Effect of oral probenecid coadministration on the pharmacokinetics of intravenous cidofovir in cynomolgus monkeys. Toxicol. Sci. 44:97-106.
17. Martinez, M. J., M. Bray, and J. Huggins. 2000. A mouse model of aerosol-transmitted orthopoxviral disease: morphology of experimental aerosol-transmitted orthopoxviral disease in a cowpox virus-BALB/c mouse system. Arch. Pathol. Lab. Med. 124:362-377.
18. Naessens, L., R. Snoeck, G. Andrei, J. Balzarini, J. Neyts, and E. de Clercq. 1997. HPMPC (cidofovir), PMEA(adefovir), and related acyclic nucleoside phosphonate analogues: a review of their pharmacology and clinical potential in the treatment of viral infections. Antivir. Chem. Chemother. 8:1-23.
19. Roy, C. J., J. M. Hartings, M. Hale, S. Duniho, and L. M. Pitt. 2003. Impact of inhalation exposure modality and particle size on the respiratory deposition of ricin in BALB/c mice. Inhal. Toxicol. 15:619-628.
20. Smee, D. F., K. W. Bailey, M. H. Wong, and R. W. Sidwell. 2001. Effects of cidofovir on the pathogenenesis of a lethal vaccinia virus respiratory infection in mice. Antivir. Res. 52:55-62.
21. Smee, D. F., K. W. Bailey, M. Wong, and R. W. Sidwell. 2000. Intranasal treatment of cowpox virus respiratory infections in mice with cidofovir. Antivir. Res. 47:171-177.
22. Smee, D. F., R. Sidwell, D. Kefauver, M. Bray, and J. Huggins. 2002. Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses. Antimicrob. Agents Chemother. 46:1329-1335.
23. Snoeck, R., and E. de Clercq. 2002. Role of cidofovir in the treatment of DNA virus infections, other than CMV infections, in immunocompromised patients. Curr. Opin. Investig. Drugs 3:1561-1566.
24. Wachsman, M., B. Petty, K. Cundy, H. Jaffe, P. Fisher, A. Pastelak, and P. Lietman. 1996. Pharmacokinetics, safety, and bioavailability of HPMPC (cidofovir) in human immunodeficiency virus-infected subjects. Antivir. Res. 29:153-161.
25. Wehrle, P. F., P. Posch, K. Richter, and D. A. Henderson. 1970. An air-borne outbreak of smallpox in a German hospital and its significance with respect to other recent outbreaks in Europe. Bull. W. H. O. 43:669-679.